Journal of International Oncology››2024,Vol. 51››Issue (8): 538-541.doi:10.3760/cma.j.cn371439-20231130-00090
Previous ArticlesNext Articles
Received:2023-11-30Revised:2024-04-10Online:2024-08-08Published:2024-09-24
"
"
"
"
| [1] | 张志强, 马怡, 郑爽, 等. 实体肿瘤治疗效果评价标准的研究进展[J].中国临床实用医学,2019,10(2): 71-73. DOI:10.3760/cma.j.issn.1673-8799.2019.02.020. |
| [2] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3): 209-249. DOI:10.3322/caac.21660. |
| [3] | Bredin P, Walshe JM, Denduluri N. Systemic therapy for metastatic HER2-positive breast cancer[J].Semin Oncol,2020,47(5): 259-269. DOI:10.1053/j.seminoncol.2020.07.008. pmid:32896428 |
| [4] | Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J].N Engl J Med,2001,344(11): 783-792. DOI:10.1056/NEJM200103153441101. |
| [5] | Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J].J Clin Oncol,2005,23(19): 4265-4274. DOI:10.1200/JCO.2005.04.173. |
| [6] | Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data[J].Ann Oncol,2001,12Suppl 1: S57-S62. |
| [7] | Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J].J Clin Oncol,2014,32(33): 3744-3752. DOI:10.1200/JCO.2014.55.5730. pmid:25332249 |
| [8] | Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the national surgical adjuvant breast and bowel project B-31 and the North central cancer treatment group N9831 clinical trials[J].J Clin Oncol,2010,28(21): 3416-3421. DOI:10.1200/JCO.2009.23.6950. pmid:20530275 |
| [9] | Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial[J].Lancet,2017,389(10075): 1195-1205. DOI:10.1016/S0140-6736(16)32616-2. pmid:28215665 |
| [10] | Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med,2011,365(14): 1273-1283. DOI:10.1056/NEJMoa0910383. |
| [11] | Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J].J Clin Oncol,2009,27(34): 5685-5692. DOI:10.1200/JCO.2008.21.4577. pmid:19884557 |
| [12] | Valero V, Forbes J, Pegram MD, et al. Multicenter phase Ⅲ randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer(BCIRG 007 study): two highly active therapeutic regimens[J].J Clin Oncol,2011,29(2): 149-156. DOI:10.1200/JCO.2010.28.6450. |
| [13] | Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J].Lancet Oncol,2020,21(4): 519-530. DOI:10.1016/S1470-2045(19)30863-0. pmid:32171426 |
| [14] | 韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J].中华普通外科学文献(电子版),2021,15(6): 453-458. DOI:10.3877/cma.j.issn.1674-0793.2021.06.013. |
| [15] | 边莉, 徐兵河, 邸立军, 等. 重组抗HER2人源化单克隆抗体联合长春瑞滨治疗HER2阳性转移性乳腺癌随机对照Ⅲ期临床研究[J].中华医学杂志,2020,100(30): 2351-2357. DOI:10.3760/cma.j.cn112137-20200116-00105. |
| [16] | Wang T, Zhang P, Di LJ, et al. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study[J].Transl Breast Cancer Res,2022,3: 15. DOI:10.21037/tbcr-21-42. pmid:38751509 |
| [17] | Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer[J].J Clin Oncol,2006,24(18): 2786-2792. DOI:10.1200/JCO.2005.04.1764. |
| [18] | Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase Ⅱ trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J].J Clin Oncol,2010,28(6): 976-983. DOI:10.1200/JCO.2008.21.6531. pmid:20038734 |
| [19] | Xu BH, Li W, Zhang QY, et al. Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase Ⅲ, randomized, double-blind, placebo-controlled study[J].Breast Cancer Res Treat,2023,197(3): 503-513. DOI:10.1007/s10549-022-06775-1. |
| [20] | 王晓闻, 刘培培, 吕锋华, 等. 抗HER2人源化单克隆抗体药物关键质量属性评价[J].中国药学杂志,2015,50(12): 1054-1061. DOI:10.11669/cpj.2015.12.014. |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
